Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant Melanoma: Southwest Oncology Group S0508

PURPOSE: In limited institution Phase II studies, thalidomide and temozolomide has yielded response rates (RR) up to 32% for advanced melanoma, leading to the use of this combination as “standard” by some. We conducted a multi-center Phase II trial to better define the clinical efficacy of thalidomi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Clark, Joseph I., Moon, James, Hutchins, Laura F., Sosman, Jeffrey A., Kast, W. Martin, Da Silva, Diane M., Liu, P.Y., Thompson, John A., Flaherty, Lawrence E., Sondak, Vernon K.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2811758/
https://ncbi.nlm.nih.gov/pubmed/19918923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24739
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares